Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

$ENTB Subsidiary Zander Therapeutics Raises $900,000 While Awaiting Clearance Of Their S-1 Filing/Registration

|Includes: Entest BioMedical Inc. (ENTB)

Summary

Capital Raise

BioTech-Stem Cell

Progressive New Drugs & Treaments

Cell Inhibitors with Cancer Killing Potential

ENTEST BIOMEDICAL, INC. (Form: 8-K, Received: 10/26/2017 10:27:23)

Zander Therapeutics has started the process of Spinning Off and becoming an Independent Publicly Traded Company - They await clearance from the SEC for their S-1 Filing/Registration.

Further updates will be provided

$ENTB-Zander Therapeutics – Big Pharma Like Bristol Myers Squibb Are Battling to Buy Undervalued Stem Cell Companies

Recently Bristol Myers Squibb acquired IMF Therapeutics for $2,300,000 - $2.3 Billion

Zander Therapeutics, Inc.

Entest BioMedical’s subsidiary Zander Therapeutics is a “Cutting Edge-Undervalued” Small Stem Cell focusing on new veterinary drugs and treatments

NR2F6 Is a Cell Inhibitor with Cancer Killing Potential and Auto-Immune Treatments-Utilizing Patients (Human & Animal) Own Immune System**

Zander is Licensed to use (NR2F6) by Entest via Regen BioPharma (OTCQB:RGBP)* www.regenbiopharmainc.com 

Zander Therapeutics is making major discoveries and progress in creating new drugs & treatments for the veterinary industry.

ZT 100 is a NR2F6 inhibitor for Feline Leukemia

ZT 240 is a NR2F6 inhibitor for Canine Cancer

ZT 369 is a NR2F6 stimulator for (EIPH) exercise induced pulmonary hemorrhage (Equine)

ZT 430 is a stimulator for arthritis and auto immunity (Feline & Canine) 

Zander Therapeutics, Inc. Reports Research Demonstrating Ex-Vivo Immune Suppression of IL-17a and IL-2 in Dogs with Novel NR2F6 Activators

“Thus far, they have met each & every scientific target, and believe that planned scientific efforts in 2018 will greatly increase the likelihood of striking strategic partnerships with one or more large pharmaceutical companies, in the near future.”

Another recent news item that could put Zander Therapeutics on the map in the Veterinary World is the announcement of the Former Petco CEO joining the company.

ENTB Announces Brian Devine, Former Chairman of PETCO, to Head its Business Advisory Board

This could one day lead to a Presence with PETCO or Other Veterinary/Pet Big Box Businesses.

We believe $ENTB although inexpensive as stocks come, is an excellent Long Play Small/Micro Cap that has the potential for Short Term Gains/Profits in the right climate and situations. They Retired All Debt not long ago.

It does need more visibility, which we are creating. More volume, positive volume, buying volume will allow for growth and an increase in share price.

Eventually this company will be noticed as a force in the veterinary medicine world. Will you be too late?

Take a close look at this little (DITR) Diamond in the Rough, the future could lead to agreements with Big Box Pet Stores (PETCO), and Vets all over the world, etc. For more information concerning $ENTB contact us and/or visit:

Yahoo Finance - Business Finance, Stock Market, Quotes, News or www.otcmarkets.com

Robert E. Kreh (Rob) - Principal

Small Cap Solutions, LLC

robkreh@smallcapsolutions.com   robkreh@gmail.com      

 (ENTB ) Disclaimer: You are receiving this because you have requested the information contained in this email, and/or have expressed an interest recently, or in the past to be included in such emails. And/or have requested information/news/updates for Entest Biomedical, Inc. This profile has been compiled by Small Cap Solutions, LLC based on information from the company believed to be true/factual. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at www.otcmarkets.com. Small Cap Solutions, LLC has received ($1000.00) cash from Value Quest, Inc. for investor relations services rendered for Entest Biomedical, Inc.(Zander Therapeutics) Additional inquiries are available by email to robkreh@smallcapsolutions.com or in writing to Small Cap Solutions, LLC 303 Joppa Crossing Ct (Suite #1) Joppa, Md. 21085 This is not a solicitation to buy or sell securities. To "unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclaimer: All Micro/Small Cap Company(ies) profile(S) are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein.

Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at yahoofinance.com and/or otcmarkets.com Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered.

Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker(S)/Broker Dealer(S) with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to robkreh@smallcapsolutions.comor by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.